The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Randomized Pilot Trial of Eight Weeks of Bedaquiline (TMC207) Treatment for Multidrug-Resistant Tuberculosis: Long-Term Outcome, Tolerability, and Effect on Emergence of Drug Resistance
Open accessAbstract
The 2-year follow-up results for a randomized placebo-controlled study of 47 patients with multidrug-resistant pulmonary tuberculosis treated with either the new diarylquinoline TMC207, recently renamed bedaquiline, or placebo, added to the first 8 weeks of a background regimen, are presented. Bedaquiline significantly reduced the time to culture conversion over 24 weeks (hazard ratio, 2.253; 95% confidence interval, 1.08 to 4.71; P = 0.031). With the exception of nausea reported in 26% of patients receiving bedaquiline and none receiving placebo, adverse events occurred at similar frequencies in both groups of patients: bilateral hearing impairment, extremity pain, acne, and noncardiac chest pain occurred in 13 and 21%, 17 and 13%, 9 and 17%, and 4 and 17% of patients, respectively, receiving bedaquiline or placebo. Excluding resistance to ethambutol and ethionamide, only one patient receiving bedaquiline acquired resistance to companion drugs, but five patients receiving placebo (4.8% versus 21.7%; P = 0.18) acquired resistance to companion drugs, and resistance to ofloxacin was acquired in four patients receiving placebo and none receiving bedaquiline (0% versus 22%; 0 = 0.066). In all, 23 patients (49%), including 13 receiving placebo (54%) and 10 receiving bedaquiline (44%), discontinued the study prior to its completion, 12 during the first 24 weeks of treatment. Eight subjects were withdrawn for noncompliance or default, and seven withdrew consent, citing the rigorous program of investigations for safety and pharmacokinetic monitoring. Bedaquiline may contribute to the management of multidrug-resistant tuberculosis by effecting more rapid sputum culture negativity and by preventing acquired resistance to companion drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H. W. H., Neefs, J.-M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., et al. (2005) · Science · doi:10.1126/science.1106753 · Cited by 2,191 · cited 1×
“TMC207, recently renamed bedaquiline, is a diarylquinoline with a novel mode of action specifically inhibiting mycobacterial ATP synthase (1).”
BackgroundSelf-citationGlobal tuberculosis control 2010
Behera, D. (2012) · The Indian Journal of Medical Research · Cited by 1,262
Palomino, J.-C., Martin, A., Camacho, M., Guerra, H., Swings, J., & Portaels, F. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.8.2720-2722.2002 · Cited by 1,229
WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update
Falzon, D., Jaramillo, E., Schünemann, H. J., Arentz, M., Bauer, M., Bayona, J., Blanc, L., Caminero, J. A., Daley, C. L., Duncombe, C., et al. (2011) · European Respiratory Journal · doi:10.1183/09031936.00073611 · Cited by 1,100
The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis
Diacon, A. H., Pym, A., Grobusch, M., Patientia, R., Rustomjee, R., Page-Shipp, L., Pistorius, C., Krause, R., Bogoshi, M., Churchyard, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808427 · Cited by 835
Self-citationTreatment and Outcome Analysis of 205 Patients with Multidrug-resistant Tuberculosis
Chan, E. D., Laurel, V., Strand, M. J., Chan, J. F., Huynh, M.-L. N., Goble, M., & Iseman, M. D. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200308-1159oc · Cited by 336
Public Health Mycobacteriology
Kent, P. (1985) · Medical Entomology and Zoology · Cited by 328
Rustomjee, R., Diacon, A. H., Allen, J., Venter, A., Reddy, C., Patientia, R. F., Mthiyane, T. C. P., De Marez, T., van Heeswijk, R., Kerstens, R., et al. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01204-07 · Cited by 278
Self-citationDrug-Induced Phospholipidosis: Are There Functional Consequences?
Reasor, M. J., & Kacew, S. (2001) · Experimental Biology and Medicine · doi:10.1177/153537020122600903 · Cited by 265
Calver, A. D., Falmer, A. A., Murray, M. B., Strauss, O. J., Streicher, E. M., Hanekom, M., Liversage, T., Masibi, M., van Helden, P. D., Warren, R. M., et al. (2010) · Emerging infectious diseases · doi:10.3201/eid1602.090968 · Cited by 143
Canetti, G., Rist, N., & Grosset, J. H. E. (1963) · PubMed · Cited by 138
Early Outcomes of MDR-TB Treatment in a High HIV-Prevalence Setting in Southern Africa
Seung, K. J., Omatayo, D. B., Keshavjee, S. A., Furin, J. J., Farmer, P. E., & Satti, H. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007186 · Cited by 122
Phospholipidosis as a Function of Basicity, Lipophilicity, and Volume of Distribution of Compounds
Hanumegowda, U., Wenke, G., Regueiro‐Ren, A., Yordanova, R., Corradi, J., & Adams, S. P. (2010) · Chemical Research in Toxicology · doi:10.1021/tx9003825 · Cited by 105
Mesens, N., Steemans, M., Hansen, E., et al. (2010) · Toxicology in Vitro · doi:10.1016/j.tiv.2010.04.007 · Cited by 34
Şatana, D., Çoban, A. Y., & Uzun, M. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.00688-10 · Cited by 9
Cited by
Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline
Diacon, A. H., Pym, A., Grobusch, M. P., de los Rios, J. M., Gotuzzo, E., Vasilyeva, I., Leimane, V., Andries, K., Bakare, N., De Marez, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313865 · Cited by 746
Self-citationDheda, K., Gumbo, T., Maartens, G., Dooley, K. E., McNerney, R., Murray, M., Furin, J., Nardell, E. A., London, L., Lessem, E., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30079-6 · Cited by 684
Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis
Pethe, K., Bifani, P., Jang, J., Kang, S., Park, S., Ahn, S., Jiricek, J., Jung, J., Jeon, H. K., Cechetto, J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3262 · Cited by 603
Hartkoorn, R. C., Uplekar, S., & Cole, S. T. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00037-14 · Cited by 489
Acquired Resistance of Mycobacterium tuberculosis to Bedaquiline
Andries, K., Villellas, C., Coeck, N., Thys, K., Gevers, T., Vranckx, L., Lounis, N., de Jong, B. C., & Koul, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102135 · Cited by 439
Self-citation
Metadata
- Authors
- Diacon, A. H., Donald, P. R., Pym, A., Grobusch, M., Patientia, R. F., Mahanyele, R., Bantubani, N., Narasimooloo, R., De Marez, T., van Heeswijk, R., Lounis, N., Meyvisch, P., Andries, K., & McNeeley, D. F.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2012-06
- Volume
- 56
- Issue
- 6
- Pages
- 3271-3276
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2164918529
- Cited by
- 377
- References
- 15
- FWCI
- 29.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.